Health Boards
Sat-06-01-2024, 14:40 PM
(This post was last modified: Sat-06-01-2024, 14:42 PM by Caroline. Edited 2 times in total.)
(Sat-06-01-2024, 13:44 PM)Fred Wrote: Efficacy of long-term Skyrizi (risankizumab) treatment for moderate-to-severe plaque psoriasis over 256 weeks.
Quote:
Background:
Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis.
Source: onlinelibrary.wiley.com
*Early view funding unknown
Skyrizi (risankizumab)
Always when I see this intro’s, I get irritated..
The people who do this research are supposedly very well trained and highly educated.
They are working on a skin disease, they say over here. My feeling then says, that you will treat the skin….
But……. No… They are treating the immune system (Skyrizi is an IL-23 suppressor). So why are you treating the immune system, while you are talking about a skin disease… That is plain stupid.
Because if you treat the immune system, there must me something wrong in this immune system, right?
If there is something wrong with your eye, you treat the eye.
If there is something wrong with your leg, stretched or broken, then you treat the leg.
In both situations above, you might also give broader treatment to fight infection.
But in the case of psoriasis AND Psoriatic Arthritis, you only treat the immune system, as this really has the right effect.
So what they really are treating, is an Immune Mediated Inflamatory Disease that manifests on the skin AND in (20-30-40%???) of the cases in the joints.
Stupid researchers.
